U.S. Lawmakers Demand Merck’s China Trial Data by July 17 over Security Risks
MRK•U.S. House lawmakers have launched a national security probe into Merck’s China-based clinical trials, demanding due diligence and data protection records by July 17, particularly in Xinjiang and military hospitals. Investigators are examining whether trial practices could enhance China’s military biotech capabilities, raising ethical and regulatory compliance concerns for Merck.
1. U.S. House Committee Investigation
A bipartisan group of U.S. Representatives has opened a national security inquiry into Merck’s involvement in China-based clinical trials. Lawmakers led by the China Select Committee chair have requested detailed records of due diligence, data protection processes and operational standards by July 17.
2. Focus on Xinjiang and Military Hospitals
The letters highlight trials conducted in the Xinjiang region and at Chinese military hospitals, citing documented lapses in informed consent and potential involvement of forced labor. Investigators are probing whether these practices inadvertently supported military research and breached ethical guidelines.
3. Potential Impacts on Merck
Merck has emphasized its commitment to patient safety and global ethical standards in clinical research. The investigation introduces regulatory scrutiny that could delay ongoing trials, affect investor confidence and prompt reviews of Merck’s broader compliance and risk management frameworks.
